前列腺癌的分子病理学研究  

Molecular pathological of prostate carcinoma

作　　者：李燕[1] 周志毅[1] 石群立[1] 

机构地区：[1]南京军区南京总医院南京大学医学院临床学院病理科,江苏南京210002

出　　处：《医学研究生学报》2007年第10期1088-1093,共6页Journal of Medical Postgraduates

基　　金：江苏省"六大人才高峰"基金资助项目(批准号:2005A2)

摘　　要：病理学分级及临床分期对前列腺癌的预后评价存在一定的局限性。运用灵敏的诊断方法和特异性的肿瘤标记物对临床早期发现前列腺癌至关重要。近年来,凋亡相关基因和肿瘤抑制基因在前列腺癌发生发展中的作用及其判断预后的价值倍受关注。前列腺癌相关的酶或蛋白以及相关激素受体的作用在前列腺癌研究中也越来越受到人们的重视。The pathologic grading and clinical staging systems have some restrictions for the evaluation of the prognosis of prostate cancer. Early detection of prostate cancer with clinically sensitive diagnostic methods and / or tumor specific markers is of prime importance. Recently, close attention has been paid to the effects of genes related to apoptosis and tumor suppressor genes on the development, progression and prognostic value of prostate cancer. The importance of enzymes/proteins and hormone receptors have also received more and more emphasis in the studies of prostate cancer .

关 键 词：前列腺癌 肿瘤标记物 肿瘤抑制基因 

分 类 号：R737.25[医药卫生—肿瘤]